Patricia Ann Duffy

Array ( [id] => 15435399 [patent_doc_number] => 20200031883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => CHANNELRHODOPSINS FOR OPTICAL CONTROL OF CELLS [patent_app_type] => utility [patent_app_number] => 16/570429 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16570429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18427668 [patent_doc_number] => 11672869 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Functionalization of bacterial effector translocase protein by chemical conjugation [patent_app_type] => utility [patent_app_number] => 16/550036 [patent_app_country] => US [patent_app_date] => 2019-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 35 [patent_no_of_words] => 17040 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16550036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15524777 [patent_doc_number] => 20200054694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => TOPICAL COMPOSITION, PHARMACEUTICAL COMPOSITION CONTAINING INACTIVATED CULTURE AND METHOD OF FACILITATING WOUND HEALING AND SCAR REDUCTION USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/539450 [patent_app_country] => US [patent_app_date] => 2019-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16539450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15147739 [patent_doc_number] => 20190352347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => CHANNELRHODOPSINS FOR OPTICAL CONTROL OF CELLS [patent_app_type] => utility [patent_app_number] => 16/530047 [patent_app_country] => US [patent_app_date] => 2019-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16530047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15210625 [patent_doc_number] => 20190367999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS [patent_app_type] => utility [patent_app_number] => 16/457186 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12338 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16457186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15210627 [patent_doc_number] => 20190368000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS [patent_app_type] => utility [patent_app_number] => 16/457244 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12340 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16457244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17815395 [patent_doc_number] => 11420993 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Semi-synthetic meningococcal conjugate vaccine [patent_app_type] => utility [patent_app_number] => 16/437561 [patent_app_country] => US [patent_app_date] => 2019-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 5647 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16437561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209753 [patent_doc_number] => 20190367563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => COMPOSITIONS AND METHODS OF DETERMINING A LEVEL OF INFECTION IN A SUBJECT [patent_app_type] => utility [patent_app_number] => 16/433798 [patent_app_country] => US [patent_app_date] => 2019-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408553 [patent_doc_number] => 20200024598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => ISOLATED POLYNUCLEOTIDE COMPRISING PROMOTER REGION, HOST CELL COMPRISING THE SAME, AND METHOD OF EXPRESSING TARGET GENE IN THE HOST CELL [patent_app_type] => utility [patent_app_number] => 16/370381 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16370381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464693 [patent_doc_number] => 20190183986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => CELL MEMBRANE TRANSLOCATION OF REGULATED SNARE INHIBITORS, COMPOSITIONS THEREFOR, AND METHODS FOR TREATMENT OF DISEASE [patent_app_type] => utility [patent_app_number] => 16/283688 [patent_app_country] => US [patent_app_date] => 2019-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -113 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16283688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712863 [patent_doc_number] => 20190247495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => NOVEL SYNTHETIC ANTICANCER, ANTIFUNGAL, AND ANTIBACTERIAL VACCINES [patent_app_type] => utility [patent_app_number] => 16/280213 [patent_app_country] => US [patent_app_date] => 2019-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37626 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16280213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14435695 [patent_doc_number] => 20190175719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => Attenuated Bordetella Strains [patent_app_type] => utility [patent_app_number] => 16/278562 [patent_app_country] => US [patent_app_date] => 2019-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12606 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16278562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14377627 [patent_doc_number] => 20190162726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => ANTI-T. CRUZI ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/237106 [patent_app_country] => US [patent_app_date] => 2018-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16237106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16519459 [patent_doc_number] => 10870669 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-22 [patent_title] => Method for producing an isolated monoclonal antibody specifically binding to a glycolipid antigen of [patent_app_type] => utility [patent_app_number] => 16/234477 [patent_app_country] => US [patent_app_date] => 2018-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 12 [patent_no_of_words] => 10862 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16234477 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17163173 [patent_doc_number] => 11149262 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-19 [patent_title] => Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation [patent_app_type] => utility [patent_app_number] => 16/227027 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 35947 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16227027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16843128 [patent_doc_number] => 11015202 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-25 [patent_title] => Complex containing oligonucleotide having immunopotentiating activity and use thereof [patent_app_type] => utility [patent_app_number] => 16/227902 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 47 [patent_no_of_words] => 15797 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16227902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915860 [patent_doc_number] => 20210188952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => HUMANIZED 2C7 MONOCLONAL ANTIBODY DIRECTED AGAINST A NEISSERIA GONORRHOEAE LIPOOLIGOSACCHARIDE (LOS) EPITOPE, FOR HUMAN USE [patent_app_type] => utility [patent_app_number] => 16/762032 [patent_app_country] => US [patent_app_date] => 2018-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16762032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16175490 [patent_doc_number] => 20200222458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => METHOD FOR PREPARING CELL EXTRACT COMPONENT OR COMPOSITION HAVING CYTOCIDAL ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/651330 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11786 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16651330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793397 [patent_doc_number] => 20190010237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => ANTI-PRLR ANTIBODY-DRUG CONJUGATES (ADC) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/139719 [patent_app_country] => US [patent_app_date] => 2018-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16139719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14040881 [patent_doc_number] => 20190076547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => ANTIBODY ADJUVANT CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/140309 [patent_app_country] => US [patent_app_date] => 2018-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70282 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16140309 [rel_patent_id] =>[rel_patent_doc_number] =>)